Skip to content

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$509M+9.9%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%
Amgen logo
AmgenAMGN
$1.12B-19.5%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$102K-20.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%
Vor Biopharma logo
Vor BiopharmaVOR
$28K-96.6%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s D&A?
Shattuck Labs, Inc. (STTK) reported D&A of $891K in Q1 2026.
How has Shattuck Labs, Inc.'s D&A changed year-over-year?
Shattuck Labs, Inc.'s D&A decreased by 4.8% year-over-year, from $936K to $891K.
What is the long-term trend for Shattuck Labs, Inc.'s D&A?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s D&A has grown at a 27.9% compound annual growth rate (CAGR), from $1.38M to $3.69M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.